Werewolf Therapeutics, Inc.
Activatable interleukin 12 polypeptides
Last updated:
Abstract:
The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
Status:
Grant
Type:
Utility
Filling date:
11 Jun 2019
Issue date:
30 Jun 2020